# A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men

> **NCT02138799** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 28 (actual)

## Conditions studied

- Drug-Drug Interaction (DDI)
- Healthy Subjects
- Pharmacokinetics of Enzalutamide

## Interventions

- **DRUG:** enzalutamide
- **DRUG:** rifampin

## Key facts

- **NCT ID:** NCT02138799
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02138799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02138799, "A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02138799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*